A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

NCT05231785 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Early-Onset Alzheimer Disease

Interventions

DRUG: ALN-APP
DRUG: Placebo

Sponsor

Alnylam Pharmaceuticals